Appy times: Venaxis back on track
This article was originally published in Clinica
After a long road with its APPY1 appendicitis test, Venaxis (formerly AspenBio Pharma) could finally be turning the corner. US FDA approval of the diagnostic is expected in the first half of 2014, according to Canaccord Genuity analyst Jeff Frelick, who rates the company’s stock as “buy” with a target price of $7. Its shares on the Nasdaq Capital Market closed at $2.16 on 27 March.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.